Academic Journal
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
| العنوان: | Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults |
|---|---|
| المؤلفون: | Tianyu Sun, Linwei Li, Katherine E. Mues, Mihaela V. Georgieva, Brenna Kirk, James A. Mansi, Nicolas Van de Velde, Ekkehard C. Beck |
| المصدر: | Infectious Diseases and Therapy, Vol 13, Iss 8, Pp 1771-1787 (2024) |
| بيانات النشر: | Adis, Springer Healthcare, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Infectious and parasitic diseases |
| مصطلحات موضوعية: | COVID-19, Immunocompromised, mRNA-1273, SARS-CoV-2, Vaccine effectiveness, Infectious and parasitic diseases, RC109-216 |
| الوصف: | Abstract Introduction Recent data have shown elevated infection rates in several subpopulations at risk of SARS-CoV-2 infection and COVID-19, including immunocompromised (IC) individuals. Previous research suggests that IC persons have reduced risks of hospitalization and medically attended COVID-19 with two doses of mRNA-1273 (SpikeVax; Moderna) compared to two doses of BNT162b2 (Comirnaty; Pfizer/BioNTech). The main objective of this retrospective cohort study was to compare real-world effectiveness of third doses of mRNA-1273 versus BNT162b2 at multiple time points on occurrence of COVID-19 hospitalization and medically attended COVID-19 among IC adults in the United States (US). Methods This retrospective, observational comparative effectiveness study identified patients from the US HealthVerity database from December 11, 2020, through August 31, 2022. Medically attended SARS-CoV-2 infections and hospitalizations were assessed following a three-dose mRNA-1273 versus BNT162b2 regimen. Inverse probability weighting was applied to balance baseline confounders between vaccine groups. Relative risk (RR) and risk difference were calculated for subgroup and sensitivity analyses using a non-parametric method. Results In propensity score-adjusted analyses, receiving mRNA-1273 vs. BNT162b2 as third dose was associated with 32.4% (relative risk 0.676; 95% confidence interval 0.506–0.887), 29.3% (0.707; 0.573–0.858), and 23.4% (0.766; 0.626–0.927) lower risk of COVID-19 hospitalization after 90, 180, and 270 days, respectively. Corresponding reductions in medically attended COVID-19 were 8.4% (0.916; 0.860–0.976), 6.4% (0.936; 0.895–0.978), and 2.4% (0.976; 0.935–1.017), respectively. Conclusions Our findings suggest a third dose of mRNA-1273 is more effective than a third dose of BNT162b2 in preventing COVID-19 hospitalization and breakthrough medically attended COVID-19 among IC adults in the US. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8229 2193-6382 |
| Relation: | https://doaj.org/toc/2193-8229; https://doaj.org/toc/2193-6382 |
| DOI: | 10.1007/s40121-024-01005-1 |
| URL الوصول: | https://doaj.org/article/135bc195a5a842ecb560c5f0ed540e50 |
| رقم الانضمام: | edsdoj.135bc195a5a842ecb560c5f0ed540e50 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 21938229 21936382 |
|---|---|
| DOI: | 10.1007/s40121-024-01005-1 |